Comparing Two Doses of Ipilimumab

Publication
Article
Special ReportsMelanoma (Issue 4)
Volume 4
Issue 1

Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).

Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).

<<<

Back to the Melanoma Special Report

Articles in this issue
Unprecedented Response Rates Seen With Ipilimumab Plus Nivolumab in Melanoma
Unprecedented Response Rates Seen With Ipilimumab Plus Nivolumab in Melanoma
Toxicity of Immunotherapies in Melanoma
Toxicity of Immunotherapies in Melanoma
Comparing Two Doses of Ipilimumab
Comparing Two Doses of Ipilimumab
New Standards Needed to Lessen Surgery Delays in Melanoma
New Standards Needed to Lessen Surgery Delays in Melanoma
Neoantigens for Personalized Immunotherapy May Boost Melanoma Treatment
Neoantigens for Personalized Immunotherapy May Boost Melanoma Treatment
Gene Removal May Pose Future Treatment in Advanced Melanoma
Gene Removal May Pose Future Treatment in Advanced Melanoma
The Development of T-VEC for Melanoma
The Development of T-VEC for Melanoma
The Role of Macrophages in BRAF Inhibitor Resistance
The Role of Macrophages in BRAF Inhibitor Resistance
Related Videos
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on skin cancer
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Related Content
To Detect More Alterations, Consider Adding Companion Testing to NGS

To Detect More Alterations, Consider Adding Companion Testing to NGS

April 19th 2024
Article

Druggable gene aberrations and predictive biomarkers has allowed for the use of next-generation sequencing technologies to grow.

Read More

Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen

Shift to Value-Based Care Brings New Desires for EHR Capabilities

Shift to Value-Based Care Brings New Desires for EHR Capabilities

April 18th 2024
Article

A survey shows doctors are looking to upgrade their EHR systems to better support value-based care by collecting patient outcome data and integrating with AI.

Read More

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

February 15th 2022
Podcast

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

Listen

The Myeloma Trial Result I Did Not See Coming

The Myeloma Trial Result I Did Not See Coming

April 17th 2024
Article

A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.

Read More

Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia

Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia

April 17th 2024
Article

During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.

Read More